Literature DB >> 34866099

Cogan Syndrome with Aortic Regurgitation and Multiple Vasculopathy.

Kohei Saiin1, Takao Konishi1, Keita Ninagawa2, Toshihisa Anzai1.   

Abstract

Entities:  

Keywords:  Cogan syndrome; aortic regurgitation; vasculopathy

Mesh:

Year:  2021        PMID: 34866099      PMCID: PMC9259824          DOI: 10.2169/internalmedicine.8248-21

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.282


× No keyword cloud information.
A 57-year-old woman with a history of scleritis was referred to the cardiology clinic due to palpitation. One year earlier, she had been diagnosed with Cogan syndrome (CS). Computed tomography revealed aortic wall thickening (Picture 1, left arrowheads), which improved with immunosuppressive therapy, including prednisolone, methotrexate, and tocilizumab (Picture 1, right arrows). The transthoracic echocardiography revealed severe aortic regurgitation (Picture 2, arrow). The peripheral angiography showed severe right brachial artery stenosis (Picture 3, left, arrow), and coronary angiography showed moderate stenoses of the left and right coronary arteries (Picture 3, right, arrowhead). The patient underwent aortic valve replacement. The histopathologic microphotograph derived from the resected aortic valves exhibited prominent myxomatous degeneration (Picture 4), although this finding was not specific to CS. CS is a rare and chronic vasculitis, characterized by keratitis, scleritis, arteritis, and valvulitis (1). Our observations suggest that cardiovascular diseases should be meticulously evaluated as possible comorbidities of CS, as a delayed diagnosis can be fatal.
Picture 1.
Picture 2.
Picture 3.
Picture 4.
The authors state that they have no Conflict of Interest (COI).
  1 in total

1.  Familial HLA-B*52 Vasculitis: Maternal, Atypical Cogan's Syndrome with Takayasu Arteritis-mimicking Aortitis and Filial Takayasu Arteritis.

Authors:  Satoshi Morinaka; Yohei Takano; Hiroto Tsuboi; Daisuke Goto; Takayuki Sumida
Journal:  Intern Med       Date:  2020-04-23       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.